-
SKU DIA-PSA Specificity PSA (KLK3)
Species Reactivity Human
Immunogen Recombinant peptide
Host Species Mouse
Isotype IgG1/l
Clone HAM18
Clonality (Mono-/Polyclonal) monoclonal
Application ELISA, Immunohistochemistry (IHC), Immunohistochemistry (Paraffin-embedded Sections)
Conjugation unconjugated
Dilution Immunhistochemie (IHC): 1:100-1:800
Format 0.05% NaN3, 2% BSA, in PBS (pH 7.4), lyophilisate, purified antibody (from culture supernatant)
Product line / Topic Enzymes, Tumor Marker / Biology
Intended Use for Research Use Only
Temperature - Storage 2-8°C
Temperature - Transport at room temperature
Search Code DIAPSA, FFPE, Paraffin
Manufacturer / Brand dianova
Uniprot_ID P07288
Gene_ID 354
Alias KLK3, Prostate Specific Antigen, PSA
- HAM18 has been developed for detection of prostate specific antigen (PSA) in routine formalin-fixed paraffin-embedded prostate tissue specimen to be used in brightfield immunohistochemistry but also for multicolor immunofluorescence. HAM18 has been tested for sensitivity, specificity and prognostic significance on more than 20.000 tissues. Accordingly, HAM18 stands for being the best validated anti-PSA clone.
Prostate Cancer is the most common cancer in men and PSA is the most important target for management of patients diagnosed with prostate cancer. PSA is a protease exclusively produced in prostate epithelial cells and secreted into the seminal fluid. Moreover, PSA reaches the blood stream and PSA levels have been shown to be proportional to quantity of prostate epithelial cells. Therefore serum analysis has developed the most commonly used method to detect PSA for prostate cancer prevention and to monitor response to therapy. Moreover, PSA immunohistochemistry is an important and common method for routine pathological diagnosis since it allows analysis of cellular expression profiles in prostate cancer.
In diagnostic routine, PSA (HAM18) immunohistochemistry can be used in the following applications
- Carcinoma of unknown origin: Rule out origin from a prostate cancer.
- Bladder tumor of male patients without unequivocal urothelial precursor lesion suggesting urothelial origin: Rule out origin from a prostate cancer.
- Advanced high-grade prostate cancer with rather low serum PSA levels: Low PSA expression in poorly differentiated cancer suggest that serum PSA levels may "underestimate" total tumor mass of the patient.
-
Anti-PSA (KLK3) (Hu) from Mouse (HAM18)
Cat# DIA-PSA
Size : 100µl